A Switch in Time....
Executive Summary
The UK, already a leading player in Rx-to-OTC switches, recently adopted new legislation to encourage even more. The implication: companies' prescription and consumer divisions will have to work more closely throughout a product's life cycle to devise cohesive strategies for success in both markets.
You may also be interested in...
Schering-Plough's About-Face On OTC Claritin
Just ten months after telling the FDA that granting Claritin OTC status posed a "major health risk," Schering-Plough--threatened by the genericization of its blockbuster drug and possible OTC competitors on the horizon--has changed its tune and asked the agency to approve the switch. Its a move which may presage a sea change in drug marketing as pressure could mount for other NSAs, as well as medications in other therapeutic categories, to go non-prescription.
Senexis Ltd.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Working Around Pre-Emption Rights
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.